Customer Center
Login | Register


VERIGENE® Bloodstream Infection Tests | VERIGENE® Gram-Positive Blood Culture Test

The VERIGENE® Gram-Positive Blood Culture Test (BC-GP) identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles

While conventional microbiological methods may require 2-4 days to produce bacterial identification and susceptibility results, VERIGENE BC-GP provides results within 2.5 hours of blood culture positivity.


Gram-positive bacteria are also a common source of contamination during blood draws, which results in clinically-irrelevant positive blood cultures. This can lead to inappropriate antimicrobial use1 and wasted time and cost. Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods.

Gram-Positive Blood Culture Test Specifications


Targets U.S./FDA-Cleared Outside U.S.
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus anginosus Group
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Enterococcus faecalis
Enterococcus faecium
Staphylococcus spp.
Streptococcus spp.
Micrococcus spp.  
Listeria spp.
mecA (methicillin)
vanA (vancomycin)
vanB (vancomycin)


Key Features
Automation Sample to Result
Instrumentation VERIGENE Reader and Processor SP
Workflow On-Demand and Scalable
Sample Type Positive Blood Culture Bottle
Hands-On Time <5 minutes
Run Time <2.5 hours
†For use with all commercially available continuous monitoring blood culture bottles; see VERIGENE BC-GP package insert for details.
VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IVD)
Videos and Webinars
Each Hour Counts: The Clinical and Economic Case for Rapid Sepsis Diagnostics
Each Hour Counts: Optimizing Therapy for Bloodstream Infections with Rapid Molecular Testing
Each Hour Counts: Improving Management of CRE’s and Other Antibiotic-Resistant BSI’s with Rapid Molecular Diagnostics
Each Hour Counts: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture Testing
In Their Own Words: Dr. Neelam Dhiman at med fusion & Clearpoint Diagnostic Laboratories
Justification, Validation and Implementation Best Practices for Multiplex Molecular Infectious Disease Tests
Articles and Abstracts
Evaluation Of The VERIGENE GN-BC For The Identification Of Gram Negative Bacilli And Detection Of Antibiotic Resistance Mechanisms Directly From Positive Blood Cultures
Comparison of VERIGENE BC-GP to Peptide Nucleic Acid Fluorescence in situ Hybridization (PNA-FISH) in Conjunction with mecA Gene Detection for Staphylococcus aureus Bacteremia
De-escalation of Antibiotics in Response to the VERIGENE Gram-Positive Blood Culture Assay
Effects of Blood Volume on the Performance of the VERIGENE BC-GP Assay in Pediatric Patients
Implementation and Accuracy of Rapid Molecular Diagnostics in Sepsis: Recipe for SUCCESS
Accuracy and Potential Clinical Utility of Two Rapid Molecular Panels for Detection of Bloodstream Infection
Impact of the VERIGENE Gram-Positive Blood Culture Assay in a Tertiary Care Pediatric Hospital
Rapid Diagnosis of Sepsis Using VERIGENE BC-GP and BC-GN Test: A Multicenter Evaluation in Hong Kong
Outcomes Utilizing Pharmacist Intervention and Rapid Molecular Diagnostic Technology (RMDT) in Patients with Gram-Positive Bloodstream Infections (BSI)
Comparison Between VERIGENE BC-GP And PNA-FISH Testing on the Treatment of Staphylococcus-related Blood Stream Infections (BSI)
Impact of a Rapid Molecular Diagnostic Test and Antimicrobial Stewardship on Time to Optimal Therapy in Bacteremic Patients
Antimicrobial Stewardship and the Use of VERIGENE Gram-Positive and Gram-Negative Rapid Identification System
Improved Clinical Outcomes after Implementation of Molecular Detection of Blood Culture Contaminants
Impact of Rapid Molecular Testing of Gram-Positive Blood Culture Isolates Using VERIGENE Gram-Positive Blood Culture (BC-GP) on Antimicrobial Stewardship and Clinical Outcomes within a Community Health System
Experience with Rapid Diagnostic Technology and Antimicrobial Stewardship for Patients with Gram-positive Bloodstream Infections
Development and Implementation of a Treatment Algorithm for Gram-Positive Bloodstream Infections Identified by a Gram-Positive Nucleic Acid Microarray Assay
Screening on Non-Blood Culture Isolates for Multi-Drug Resistance using the VERIGENE System
Misidentification of a Bloodstream Klebsiella variicola Infection: An Investigation in Laboratory Diagnosis
Challenges of Antimicrobial Stewardship at a Community Hospital using Rapid Identification Methods for Gram Positive Bacteremia


Learn how the VERIGENE® System provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.
Read More


Learn how the VERIGENE Gram-Negative Blood Culture Test (BC-GN) can provide results within two hours of blood culture positivity.
Read More

  1. von Eiff C, Herrmann M, Peters G. 1995. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Ag Chemo. 39:268-270.


For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.

Intended Use

The VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result VERIGENE System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.

BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, Listeria spp.

In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureus or S. epidermidis.

BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.